William Andrew Macan Sells 16,005 Shares of Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 16,005 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $1.34, for a total transaction of $21,446.70. Following the completion of the transaction, the executive vice president owned 897,270 shares of the company’s stock, valued at $1,202,341.80. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

William Andrew Macan also recently made the following trade(s):

• On Thursday, February 26th, William Andrew Macan sold 3,427 shares of Neuronetics stock. The stock was sold at an average price of $1.35, for a total transaction of $4,626.45.
• On Thursday, February 12th, William Andrew Macan sold 14,120 shares of Neuronetics stock. The stock was sold at an average price of $1.65, for a total transaction of $23,298.00.
• On Tuesday, February 10th, William Andrew Macan sold 3,485 shares of Neuronetics stock. The shares were sold at an average price of $1.55, for a total transaction of $5,401.75.

Neuronetics Trading Down 9.1%

Neuronetics stock opened at $1.46 on Wednesday. The stock has a market cap of $100.80 million, a P/E ratio of -2.47 and a beta of 0.87. Neuronetics, Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $4.97. The firm’s fifty day moving average price is $1.58 and its 200-day moving average price is $1.98. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The company had revenue of $41.78 million during the quarter, compared to analyst estimates of $40.84 million. Equities research analysts forecast that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Neuronetics

A number of hedge funds and other institutional investors have recently modified their holdings of STIM. Presidio Capital Management LLC bought a new position in shares of Neuronetics during the 3rd quarter valued at about $32,000. Intrua Financial LLC purchased a new position in shares of Neuronetics during the 3rd quarter valued at about $33,000. Sherbrooke Park Advisers LLC bought a new stake in Neuronetics in the 3rd quarter worth approximately $33,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Neuronetics in the second quarter worth approximately $34,000. Finally, Raymond James Financial Inc. purchased a new stake in Neuronetics in the second quarter worth approximately $37,000. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Neuronetics

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Company reported higher revenue, narrowed loss and set a 2026 outlook — this operational improvement and guidance can support valuation uplift. Neuronetics reports higher revenue, narrows loss, sets 2026 outlook
• Positive Sentiment: Major shareholder Jorey Chernett has been buying heavily (recent purchases total hundreds of thousands of shares across several days), signaling insider conviction and providing buying support. Neuronetics (NASDAQ:STIM) Major Shareholder Jorey Chernett Buys 169,472 Shares
• Neutral Sentiment: Board/management change — Dan Reuvers was appointed CEO, succeeding Keith Sullivan. Leadership changes introduce execution risk but may be neutral if transition is smooth. Neuronetics appoints Dan Reuvers as CEO, succeeding Keith Sullivan
• Neutral Sentiment: Analyses remain mixed — a Seeking Alpha piece calls STIM highly speculative but highlights revenue growth as a potential catalyst; this keeps sentiment bifurcated. Neuronetics: Highly Speculative, But Revenue Growth Could Drive The Stock Higher
• Neutral Sentiment: Short‑interest data released appears to contain errors (zero/NaN values), so no clear short‑pressure signal from official releases at this time.
• Negative Sentiment: Insider selling by executives and a director: EVP William Andrew Macan, EVP Steven Pfanstiel and Director Keith J. Sullivan sold shares on March 19th — such sales can be viewed negatively by the market even though insiders still retain large positions. SEC insider sale filings
• Negative Sentiment: Analyst moves and price‑target cuts: Canaccord trimmed its PT from $7 to $3 (still a buy), while other firms lowered ratings or maintained sell views — downward revisions and mixed analyst sentiment are pressuring the stock. MarketBeat STIM coverage (analyst updates)

Analysts Set New Price Targets

STIM has been the topic of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group decreased their price target on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, March 19th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.00.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.